Molecular Partners Liabilities 2025

Molecular Partners Aktienanalyse

What does Molecular Partners do?

Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years. Molecular Partners ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Molecular Partners's Liabilities

Molecular Partners's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Molecular Partners's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Molecular Partners's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Molecular Partners's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Molecular Partners’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Molecular Partners stock

What is the level of liabilities of Molecular Partners this year?

Molecular Partners has a debt balance of 21.92 M CHF this year.

What were the liabilities of Molecular Partners compared to the previous year?

The liabilities of Molecular Partners have increased by -19.08% dropped compared to the previous year.

What are the consequences of high debt for investors of Molecular Partners?

High liabilities can pose a risk for investors of Molecular Partners, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Molecular Partners?

Low liabilities mean that Molecular Partners has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Molecular Partners affect the company?

An increase in liabilities of Molecular Partners can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Molecular Partners affect the company?

A decrease in the liabilities of Molecular Partners can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Molecular Partners?

Some factors that can influence the liabilities of Molecular Partners include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Molecular Partners so important for investors?

The liabilities of Molecular Partners are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Molecular Partners take to modify the liabilities?

To change its liabilities, Molecular Partners can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Molecular Partners pay?

Over the past 12 months, Molecular Partners paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Molecular Partners is expected to pay a dividend of 0 CHF.

What is the dividend yield of Molecular Partners?

The current dividend yield of Molecular Partners is .

When does Molecular Partners pay dividends?

Molecular Partners pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Molecular Partners?

Molecular Partners paid dividends every year for the past 0 years.

What is the dividend of Molecular Partners?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Molecular Partners located?

Molecular Partners is assigned to the 'Health' sector.

Wann musste ich die Aktien von Molecular Partners kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Molecular Partners from 1/2/2025 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 1/2/2025.

When did Molecular Partners pay the last dividend?

The last dividend was paid out on 1/2/2025.

What was the dividend of Molecular Partners in the year 2024?

In the year 2024, Molecular Partners distributed 0 CHF as dividends.

In which currency does Molecular Partners pay out the dividend?

The dividends of Molecular Partners are distributed in CHF.